Cardiff Oncology, Inc. (CRDF) Misses Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts CRDF Hot Sheet
Join SI Premium – FREE
Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q2 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $62.78 thousand.
For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
- Hyperliquid Strategies to webcast fiscal year 2026 results
- Exyn Technologies, Inc. (EXYN) Reports Q2 Loss of $1.55
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
